EVENTS|NEWS|CONTACT|DONATE

Gastric Cancer
Accelerate Research
Patient Resources
Nutrition
- Eating and Healing
- Gesundheit Kitchen
  - Watch Episodes
  - Printable Recipes
Ways to Give
About Us

Read Our Newsletter

Gastric Cancer
Accelerate Research
Patient Resources
Nutrition
- Eating and Healing
- Gesundheit Kitchen
  - Watch Episodes
  - Printable Recipes
Ways to Give
About Us

Day

September 4, 2019

Guardant’s blood test tracks microsatellite instability status on par with tissue biopsy in new study

In a trial involving 949 patients with 40 tumor types, including gastric cancer, a blood test from Guardant Health was as good...

Social Media

Newsroom

For press inquiries about the Gastric Cancer Foundation, please contact: Mediainfo@gastriccancer.org

Categories

Foundation News
Press Releases
Research News
Your New Normal

Tags

adenocarcenoma advanced stage alcohol antibody biomarker blood chemoradiotherapy chemotherapy clinical trial clinical trials detection drugs endoscopy Epstein-Barr esophagogastric FDA gastrectomy gastric cancer registry gastroesophageal genes heartburn helicobacter pylori HER2 immunotherapy keytruda lonsurf metastatic nutrition peritoneal postoperative prevention proton pump inhibitor recovery recurrence research risk screening side-effects studies surgery survival treatment tumor virus women

Gastric Cancer Foundation

Tax ID 27-2978173

info@gastriccancer.org

PO Box 338
Millbrae, CA 94030

For Deliveries:
Gastric Cancer Foundation
501 Broadway, #338
Millbrae, CA 94030-1907

Site Map

Gastric Cancer
Accelerate Research
Patient Resources
Nutrition
- Eating and Healing
- Gesundheit Kitchen
  - Watch Episodes
  - Printable Recipes
Ways to Give
About Us

Social Feed

Gastric Cancer Foundation

1 week ago

AstraZeneca announced positive results from a phase 3 clinical trial combining its immunotherapy drug Imfinzi (durvalumab) with chemotherapy in some gastric cancer patients before and after surgery. More than two-thirds of patients were alive at three years, according to data presented at the European Society for Medical Oncology (ESMO) Congress. #ESMO25 ... See MoreSee Less

Imfinzi-based regimen reduced the risk of death by 22% in early gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial

www.astrazeneca.com

Imfinzi-based regimen reduced the risk of death by 22% in early gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial PUBLISHED 17 October 2025 More than two thirds of patients treated w...

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

1 month ago

Could AI be the key to improving the early diagnosis of Stomach Cancer? A recent analysis of 19 studies concluded the technology could play a promising role in diagnosis. ... See MoreSee Less

www.sciencedirect.com

www.sciencedirect.com

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

1 month ago

Stomach cancer is the fourth leading cause of cancer deaths worldwide, yet it receives less than half of one percent of U.S. federal cancer research funding. Your generosity fuels research and provides people with stomach cancer the information, support and hope they need to navigate their journey. Visit gastriccancer.org/commit-to-a-cure to learn more and support our Fall campaign. ... See MoreSee Less

We can do this together!

conta.cc

Email from Gastric Cancer Foundation Commit to a Cure DONATE Dear Friends, You may have recently received our new COMMIT TO A CURE brochure in the mail. As we launch this year’s Fall fundraising...

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

1 month ago

“Screening for Gastric Cancer: Why a personalized approach is needed for those at risk for the disease.” Via MedPage Today ... See MoreSee Less

Screening for Gastric Cancer: No Simple Answers

www.medpagetoday.com

Why a personalized approach is needed for those at risk for the disease

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

2 months ago

Two new reports conclude that eradicating H. Pylori infection can lower the risk of gastric cancer. One of the studies concluded that gastric cancer incidence falls by 40% with eradication of the bacteria. Via The New England Journal of Medicine ... See MoreSee Less

Preventing Gastric Cancer by Eradicating

www.jwatch.org

Gastric infection with Helicobacter pylori initiates mucosal changes that can evolve to adenocarcinoma. Two new reports expand our understanding of the

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Subscribe to Our Newsletter

We’ll deliver our monthly newsletter to your Inbox with Foundation updates, news about cutting edge research and trends in the field, and how to make a difference.

© 2024 Gastric Cancer Foundation. All Rights Reserved.

EVENTS | NEWS | CONTACT | DONATE

Please join with us to fuel the next wave of progress.

Your support honors the memories of those we have lost and creates much-needed hope for those who are bravely facing the disease today. Contributions are tax-deductible.

Please join with us to fuel the next wave of progress. Support our 2025 Fundraising Campaign.

Your support honors the memories of those we have lost and creates much-needed hope for those who are bravely facing the disease today. Contributions are tax-deductible.

Powering progress to defeat stomach cancer.

Powering progress to defeat stomach cancer.

MORE INFO DONATE DONATE MORE INFO

X